Who are Ovide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Thymanax, Rozerem, Rozerem, Bloxiverz, Razadyne, Aricept.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/malathion.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Ovide — Competitive Intelligence Brief

Ovide (MALATHION) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinesterase Inhibitor [EPC]. Area: Neuroscience.

marketed Cholinesterase Inhibitor [EPC] Melatonin receptor type 1A Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Ovide (MALATHION) — Taro.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ovide TARGET	MALATHION	Taro	marketed	Cholinesterase Inhibitor [EPC]	Melatonin receptor type 1A	1982-01-01
Thymanax	AGOMELATINE	Les Laboratoires Servier	marketed	agomelatine	Melatonin receptor type 1A	2009-01-01
Rozerem	RAMELTEON	Takeda	marketed	Melatonin Receptor Agonist [EPC]	Melatonin receptor type 1A	2005-01-01
Rozerem	Rozerem	Northwestern University	marketed		Melatonin receptor type 1A, Melatonin receptor type 1B
Bloxiverz	NEOSTIGMINE	Fresenius Kabi	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	2013-01-01
Razadyne	GALANTAMINE	Johnson & Johnson	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	2001-01-01
Aricept	DONEPEZIL	Eisai	marketed	Cholinesterase Inhibitor	Sigma non-opioid intracellular receptor 1	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinesterase Inhibitor [EPC] class)

Taro · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ovide — Competitive Intelligence Brief. https://druglandscape.com/ci/malathion. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab